Weill Cornell Medicine Awarded SPORE Grant in Prostate Cancer
Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.
Oncology
Ongoing Research in Early-Stage Invasive Breast Cancer Treatment
Searching for approaches to address ongoing challenges, a number of studies and clinical trials are evaluating new approaches for neoadjuvant therapies and early phase clinical trials to assess novel therapeutic agents based on tumor genomics.
Oncology
Neoadjuvant Therapy in Breast Cancer: A New Raison D’être
In the past 50 years, use of neoadjuvant chemotherapy for breast cancer has evolved. Today, clinicians at NewYork-Presbyterian are using neoadjuvant therapy to tackle residual tumor.
Oncology
Targeting Early Breast Cancers with Ablation Therapies
Surgeons at NewYork-Presbyterian/Columbia are turning up the heat (or cold as the case may be) on early-stage breast cancer tumors with the use of ablation therapies.